Kyverna Therapeutics, Inc. Finance Lease, Principal Payments
Kyverna Therapeutics, Inc. (KYTX) reported Finance Lease, Principal Payments of $181.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-11
- Kyverna Therapeutics, Inc. finance lease, principal payments for the quarter ending 2026-06-30 was $95.00K, a 63.74% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, principal payments for the quarter ending 2026-03-31 was $86.00K, a 74.78% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, principal payments for the quarter ending 2025-12-31 was $85.00K, a 65.59% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, principal payments for the quarter ending 2025-09-30 was $120.00K, a 50.21% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, principal payments for fiscal 2025 was $808.00K, a 15.48% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. finance lease, principal payments for fiscal 2024 was $956.00K, a 22.41% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. finance lease, principal payments for fiscal 2023 was $781.00K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $181.00K 10-Q · filed 2026-08-11 | $266.00K derived: sum of 3 quarters · filed 2026-08-11 | $386.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $86.00K 10-Q · filed 2026-05-12 | $171.00K derived: sum of 2 quarters · filed 2026-05-12 | $291.00K derived: sum of 3 quarters · filed 2026-05-12 | $553.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $205.00K derived: sum of 2 quarters · filed 2026-03-26 | $467.00K derived: sum of 3 quarters · filed 2026-08-11 | $808.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $382.00K derived: sum of 2 quarters · filed 2026-08-11 | $723.00K 10-Q · filed 2025-11-12 | $970.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $262.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $603.00K 10-Q · filed 2026-08-11 | $850.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $341.00K 10-Q · filed 2026-05-12 | $588.00K derived: sum of 2 quarters · filed 2026-05-12 | $829.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.07M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $488.00K derived: sum of 2 quarters · filed 2026-03-26 | $733.00K derived: sum of 3 quarters · filed 2026-03-26 | $956.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $241.00K 10-Q · filed 2024-11-13 | $486.00K derived: sum of 2 quarters · filed 2024-11-13 | $709.00K 10-Q · filed 2025-11-12 | $936.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $245.00K 10-Q · filed 2024-08-12 | $467.00K 10-Q · filed 2025-08-12 | $695.00K derived: sum of 3 quarters · filed 2025-05-13 | $901.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $231.00K 10-Q · filed 2025-05-13 | $450.00K derived: sum of 2 quarters · filed 2025-05-13 | $656.00K derived: sum of 3 quarters · filed 2025-05-13 | $843.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $425.00K derived: sum of 2 quarters · filed 2025-03-27 | $612.00K derived: sum of 3 quarters · filed 2025-03-27 | $781.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $206.00K 10-Q · filed 2024-11-13 | $393.00K derived: sum of 2 quarters · filed 2024-11-13 | $562.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $187.00K 10-Q · filed 2024-08-12 | $357.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $168.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |